Table 2.
Summary of results
| IIEF-EF baseline (mean ± SD) | IIEF-EF after treatment (mean ± SD) | Mean IIEF-EF variation after treatment | P value (Student’s t-test) | SEP3 (% yes) baseline | SEP3 (% yes) after treatment | P value (test z) | |
|---|---|---|---|---|---|---|---|
| Overall | |||||||
| Group A (L-arginine) | 15 ± 7 | 18.1 ± 9.2 | +3.1 | .0089 | 43 (43/100) | 54 (54/100) | .0007 |
| Group B (tadalafil) | 14.8 ± 6.9 | 20.8 ± 7.3 | +6 | <.0001 | 41 (41/100) | 62.6 (62/99) | <.0001 |
| Group C (L arginine + tadalafil) | 14.9 ± 7.1 | 22 ± 7.5 | +7.1 | <.0001 | 42 (42/100) | 63 (63/100) | <.0001 |
| Mild ED (IIEF-EF score 18–25) | |||||||
| Group A (L-arginine) | 22.1 ± 2.2 | 27.5 ± 2.3 | +5.4 | <.0001 | 82.9 (34/41) | 97.5 (40/41) | .0124 |
| Group B (tadalafil) | 22.1 ± 2.2 | 27.8 ± 2 | +5.7 | <.0001 | 84.2 (32/38) | 100 (38/38) | .0122 |
| Group C (L arginine + tadalafil) | 22.2 ± 2.2 | 29.3 ± 0.9 | +7.1 | <.0001 | 85 (34/40) | 100 (40/40) | .0123 |
| Moderate ED (IIEF-EF score 11–17) | |||||||
| Group A (L-arginine) | 13.5 ± 1.9 | 16 ± 3.1 | +2.5 | .0001 | 25.7 (9/35) | 40 (14/35) | .023 |
| Group B (tadalafil) | 13.8 ± 2 | 20.5 ± 2.2 | +6.7 | <.0001 | 24.3 (9/37) | 56.7 (21/37) | <.0001 |
| Group C (L arginine + tadalafil) | 13.7 ± 2 | 20.9 ± 3.3 | +7.2 | <.0001 | 22.9 (8/35) | 60 (21/35) | <.0001 |
| Severe ED (IIEF-EF score 0–10) | |||||||
| Group A (L-arginine) | 5.1 ± 2.2 | 5.2 ± 2.3 | +0.1 | .4966 | 0 (0/24) | 0 (0/24) | ND |
| Group B (tadalafil) | 5.3 ± 2.4 | 10.2 ± 4.2 | +4.9 | <.0001 | 0 (0/25) | 12.5 (3/24) | .0829 |
| Group C (L arginine + tadalafil) | 5.2 ± 2.3 | 11.8 ± 3.8 | +6.6 | <.0001 | 0 (0/25) | 8 (2/25) | .1614 |
| Test F – P value | Scheffè |
LSD |
Bonferroni |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A vs B | A vs C | B vs C | A vs B | A vs C | B vs C | A vs B | A vs C | B vs C | ||
| Overall | <.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Mild | <.0001 | ∗0.706 | <0.0001 | <0.0001 | ∗0.4051 | <0.0001 | <0.0001 | ∗NS | <0.0001 | <0.0001 |
| Moderate | <.0001 | <0.0001 | <0.0001 | ∗0.4941 | <0.0001 | <0.0001 | ∗0.2361 | <0.0001 | <0.0001 | ∗0.7082 |
| Severe | <.0001 | <0.0001 | <0.0001 | 0.0031 | <0.0001 | <0.0001 | 0.0011 | <0.0001 | <0.0001 | 0.0021 |
ED = erectile dysfunction; IIEF-EF = International Index of Erectile Function-erectile function; SD = standard deviation; SEP = Sexual Encounter Profile.
∗
There was not significant statistical difference between group A and group B in the mild-ED population and between group B and group C in the moderate ED